(searched for: doi:10.1016/j.scitotenv.2021.145530)
Current Opinion in Environmental Science & Health, Volume 21; doi:10.1016/j.coesh.2021.100254
There is a pressing drive to address climate change and environmental degradation that are global existential threats. Europe has strategically responded by unifying efforts to transform its connected communities into a modern, resource-efficient and competitive economy with a trajectory to enable net nil greenhouse gas emissions by 2050; thus, ensuring economic growth is decoupled from resource utilisation, and that no person or place is left behind. The European Green Deal is an ambitious plan to make the European economy sustainable; however, there is no reference blue-print for the safe and just transitioning to a low carbon economy. This constitutes the first description of a triple helix (academic-industry-authority) concept underpinning operation of multiactor innovation hub that can be strategically applied to enable this transition that develops green innovation and enterprises. Innovative tools for meeting the United Nations’ Sustainable Development Goals are informed by appropriate technology, policy and society readiness levels from idea to final market/wider society deployment. “Empower-Eco Sustainability HUB,” is a digitised “living lab” established in the Irish peatlands that converges academia, communities, social enterprises, industries, policy and decision-makers. It develops green innovation in intended environments at demo/test-beds, such as for digital, agri-food, bioeconomy and bio-based sectors, and embraces climate-proofing and COVID-19 recovery.
Vaccines, Volume 9; doi:10.3390/vaccines9050433
Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this objective may only be achieved by pursuing effective strategies and policies in various countries worldwide. In the present review, some aspects involved in accomplishing a successful vaccination program are addressed, in addition to the importance of vaccination in a pandemic in the face of unwillingness, conspiracy theories, or a lack of information among the public. Moreover, we provide some updated points related to the landscape of the clinical development of vaccine candidates, specifically, the top five vaccines that are already being assessed in Phase IV clinical trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, and CoronaVac).